Kaposi sarcoma (KS) is one of the Acquired Immuno-Deficiency Syndrome (AIDS)-associated malignancies and is more common in men than in women. A large international observational study cohort in the established antiretroviral (ART) era showed that the rate of AIDS-associated KS in Europe and the Americas is 6 times higher in men than in women. We report our experience with Kaposi sarcoma in women in a safety-net hospital in Atlanta, Georgia.
This is a descriptive case – series of all HIV-positive women who had a tissue diagnosis of KS between 8/1/2013 to 4/15/2018. Demographics, symptoms presentation, laboratory data, treatment, and outcomes were abstracted from the electronic medical records.
Of 102 individuals with tissue – confirmed KS during this period, there were 5 women: 4 were Black (2 were born in USA and 2 immigrated from Africa) and 1 was Caucasian. Their median age was 40 years (range: 35-56), their median CD4+ cell count at KS diagnosis was 8.3 cells/mm3 (range: 3-274) with a median log10 viral load copies/mL of 5 (range: 2.26-5.38). There was a median of 56 days (range: 26-365) from onset of symptoms to KS diagnosis. KS occurred an average of 4 years (range: 0.6-15) after HIV diagnosis. The majority had KS disease with cutaneous and visceral (pulmonary or gastrointestinal) involvement. Only 1(20%) was on ART at KS diagnosis and 4 (80%) received ART after KS diagnosis. KS was treated with liposomal doxorubicin in 2 women; 1 received radiation to her oropharyngeal lesion. One woman died shortly after her KS diagnosis from shock and multiorgan failure.
Kaposi sarcoma remains a rare but serious complication of AIDS in women. Providers should be vigilant in recognizing early signs of KS in AIDS-infected women to allow timely diagnosis and therapy of this treatable disease.
M. Mosunjac, None
M. L. Nguyen, None